For decades, conventional biomarkers such as M protein, β2 microglobulin, albumin, cytogenic alterations and bone lesions assessed using serum protein electrophoresis, FISH and imaging were used to diagnose and risk-stratify MM. The gene discussed is MYOM2; the disease is Miyoshi myopathy.